 |
7 Diseases |  |
13 Trials |
|
13 Trials |  |
1459 News |  |
| «12...567891011121314151617» |
- ||| Ajovy (fremanezumab) / Otsuka, Teva
Teva Canada Announces Product Availability of AJOVY™ https://t.co/xbSQBFh0cC (Twitter) - Aug 19, 2020
- || Review, Journal: Recent Medications Approved for Preventing Migraine Headaches. (Pubmed Central) - Aug 18, 2020
The available studies to date document that these agents reduce migraine attacks. The CGRP monoclonal antibodies offer patients new options once they have exhausted other treatments.
- || Ajovy (fremanezumab) / Otsuka, Teva
Teva's Ajovy, chasing Amgen and Lilly drugs, gains steam after autoinjector rollout https://t.co/hRsKpckyyT (Twitter) - Aug 10, 2020
- | Ajovy (fremanezumab-vfrm) / Teva
Enrollment open: A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age (clinicaltrials.gov) - Aug 7, 2020
P3, N=288, Recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
The CGRP monoclonal antibodies offer patients new options once they have exhausted other treatments. Not yet recruiting --> Recruiting
- | Ajovy (fremanezumab) / Otsuka, Teva
Enrollment open: A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age (clinicaltrials.gov) - Aug 7, 2020
P3, N=418, Recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Ajovy (fremanezumab) / Otsuka, Teva
@TevaUSA files for #Ajovy approval in Japan, where it is changing strategy https://t.co/Xm2ARFjRwX (Twitter) - Jul 30, 2020
- || Review, Journal: Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review. (Pubmed Central) - Jul 24, 2020
The four to name are: galcanezumab, fremanezumab, eptinezumab, and erenumab. The purpose of this review is to shed light on the use of these monoclonal antibodies, completed and recruiting trials, and the role of these medications in the prevention of not only EM and CM but also in medication overuse headaches.
- || TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva
Clinical, Journal: Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine. (Pubmed Central) - Jul 22, 2020
The purpose of this review is to shed light on the use of these monoclonal antibodies, completed and recruiting trials, and the role of these medications in the prevention of not only EM and CM but also in medication overuse headaches. The early onset of efficacy of fremanezumab may have the potential to improve patient compliance and clinical outcomes.
- | TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva
UK launch for #Ajovy #injectorpen https://t.co/lrLOMRFO43 @PharmaTimes @tevapharm #fremanezumab $TEVA (Twitter) - Jul 22, 2020
- | Ajovy (fremanezumab) / Otsuka, Teva
Trial completion date, Trial primary completion date: A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia (clinicaltrials.gov) - Jul 22, 2020
P2, N=240, Recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
The early onset of efficacy of fremanezumab may have the potential to improve patient compliance and clinical outcomes. Trial completion date: Aug 2022 --> Aug 2021 | Trial primary completion date: Aug 2022 --> Aug 2021
- | Review, Journal: Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. (Pubmed Central) - Jul 21, 2020
Convenient monthly dosing for the MAbs can further improve medication adherence, hence better headache control. With CGRP function-blocking therapy showing efficacy even in individuals who failed other preventives, it has become an exciting new therapeutic option in the field of migraine and CH.
- | Journal: Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists. (Pubmed Central) - Jul 16, 2020
The pathophysiology of how CGRP monoclonal antagonists might exacerbate or induce RP is discussed. The cases suggest but do not prove causation.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Work Productivity and Activity Impairment Outcomes with Fremanezumab in Patients with Migraine and Inadequate Response to 2-4 Migraine Preventive Medication Classes: Open-label Extension of FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_296;
The cases suggest but do not prove causation. Administration of fremanezumab during the OLE of the FOCUS study maintained improvements in work productivity and activity impairment, as measured by the WPAI questionnaire, in patients with EM or CM and documented inadequate response to 2-4 prior classes of migraine preventive medications.
- Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Wearing off in CGRP Fremanezumab-vfrm and Galcanezumab-gnlm () - Jul 15, 2020 - Abstract #AHS2020AHS_294;
A significant number of patients have a wearing off before their sub-sequent injection. Our findings highlight a potential confounding factor for response rates and raises questions regarding the recommended frequency of the dosing to obtain optimal migraine control
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Trending the First Two Years of Anti-calcitonin Gene-related Peptide Class Availability for Migraine Prevention: Results from an Independent Quarterly US Survey of Neurologists and Migraine Specialists () - Jul 15, 2020 - Abstract #AHS2020AHS_286;
Preferential uptake of galcanezumab, the only agent with data for multiple response rates (i.e., ≥50%, ≥75%, ≥100%) in its label, could be tied to the increasing importance of high responder rates when selecting a therapy. Eptinezumab, a once-quarterly infusion anti-CGRP, could introduce greater competitive pressure on onabotulinumtoxinA share, specifically in the chronic migraine segment.
- Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Treatment Patterns and Characteristics of Patients Prescribed AJOVY, Emgality, or Aimovig () - Jul 15, 2020 - Abstract #AHS2020AHS_284;
While patients prescribed AJOVY, Emgality, and Aimovig shared some similar baseline characteristics, there were several significant differences when comparing clinical features of patients prescribed Emgality or Aimovig vs AJOVY. The results from this descriptive analysis may contribute to understanding prescribing differences for these anti-CGRP pathway therapies and further optimize patient care for migraine.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real-world Persistence in Patients Treated with Onabotulinumtoxina or Calcitonin Gene-related Peptide Monoclonal Antibodies (CGRP Mabs) for Migraine: A Large US Administrative Claims Database Study () - Jul 15, 2020 - Abstract #AHS2020AHS_239;
These results were observed in both CM and EM populations. Future research is warranted to confirm these findings as more long-term data become available.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Profiling Physicians Prescribing Concurrent Anti-calcitonin Gene-related Peptide Monoclonal Antibody and Onabotulinumtoxina for Migraine Prevention: Results from an Annual US Patient Chart Audit () - Jul 15, 2020 - Abstract #AHS2020AHS_233;
Strong early adoption of first-to-market erenumab and shorter periods of access to the other CGRP mAb at the time of review led to onabotA being most likely to be prescribed in combination with erenumab. A prospective study of concomitant treatment with a CGRP mAb and onabotA would be instructive for clinical management.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Pooled Analysis of Tolerability with Fremanezumab Treatment in Patients with Episodic or Chronic Migraine and Cardiovascular Medication Use at Baseline () - Jul 15, 2020 - Abstract #AHS2020AHS_228;
A prospective study of concomitant treatment with a CGRP mAb and onabotA would be instructive for clinical management. This pooled analysis demonstrates that fremanezumab treatment over 12 weeks was well tolerated, with low and similar cardiac and vascular disorder AEs to placebo, in patients with migraine using CV medications at baseline.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Pooled Analysis of Cardiovascular Safety with Fremanezumab Treatment in Patients with Migraine and Concomitant Triptan Use () - Jul 15, 2020 - Abstract #AHS2020AHS_227;
This pooled analysis demonstrates that fremanezumab treatment over 12 weeks was well tolerated, with low and similar cardiac and vascular disorder AEs to placebo, in patients with migraine using CV medications at baseline. This pooled analysis demonstrates that fremanezumab treatment over 12 weeks was well tolerated in patients with migraine and concomitant triptan use, with similar CV tolerability compared to those with no triptan use.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Persistence to Onabotulinumtoxina versus Calcitonin Gene-related Peptide Monoclonal Antibodies (CGRP Mabs) Among Migraine Patients in a US Electronic Health Record Database () - Jul 15, 2020 - Abstract #AHS2020AHS_225;
This finding holds true among patients with CM and among those with EM. Future research is warranted to confirm these findings over a longer period of follow-up.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Patient Satisfaction with Fremanezumab During the Open-label Period of the Phase 3b FOCUS Study in Patients with Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications () - Jul 15, 2020 - Abstract #AHS2020AHS_220;
The improvement in patient’s general quality of life and health status, based on the PGIC, observed with fremanezumab during the DBP of the FOCUS study was generally maintained or increased during the OLE in patients with EM or CM and documented inadequate response to 2-4 prior classes of migraine preventive medications. The majority of patients were considered responders (rating of moderately better to a great deal better) on the PGIC at the end of the OLE.
- rimegepant (BHV-3000) / Portage
[VIRTUAL] Oral Rimegepant 75 Mg Is Well Tolerated When Used Concomitantly with Injectable Anti-cgrp Monoclonal Antibodies: Results from a Multicenter, Long-term, Open-label Safety Study () - Jul 15, 2020 - Abstract #AHS2020AHS_216;
P2/3
Rimegepant 75 mg, when used as an oral acute treatment for migraine in patients receiving injectable anti-CGRP mAbs for preventive treatment, demonstrated favorable tolerability and no safety issues. Studies involving larger patient populations are needed to confirm these findings.
- Emgality (galcanezumab) / Eli Lilly, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Oral Candidiasis in a Migraine Patient Taking Erenumab (Aimovig) and Galcanezumab (Emgality) () - Jul 15, 2020 - Abstract #AHS2020AHS_214;
Disruption of the IL-17 cascade from initiation of anti-CGRP medications may lead to an intrinsic proliferation of candida. The effects of long term anti-CGRP therapy on human physiology are poorly understood.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Improvements in Quality-of-life, Productivity, and Satisfaction with Fremanezumab in Migraine Patients ≥60 Years of Age: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies () - Jul 15, 2020 - Abstract #AHS2020AHS_179;
The effects of long term anti-CGRP therapy on human physiology are poorly understood. This pooled analysis demonstrates that both fremanezumab treatment regimens over 12 weeks improved HRQoL, productivity, and satisfaction, as measured by MSQoL, WPAI, and PGIC, respectively, compared with placebo in patients ≥60 years of age with EM or CM.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Improvements in Headache-related Disability with Fremanezumab in Patients ≥60 Years of Age with Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies () - Jul 15, 2020 - Abstract #AHS2020AHS_178;
This pooled analysis demonstrates that both fremanezumab treatment regimens over 12 weeks improved HRQoL, productivity, and satisfaction, as measured by MSQoL, WPAI, and PGIC, respectively, compared with placebo in patients ≥60 years of age with EM or CM. Pooled data from three phase 3 trials demonstrate that fremanezumab treatment over 12 weeks improved headache-related disability in patients ≥60 years of age with EM or CM.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Impact of Fremanezumab on Migraine-specific Quality of Life in Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_172;
Pooled data from three phase 3 trials demonstrate that fremanezumab treatment over 12 weeks improved headache-related disability in patients ≥60 years of age with EM or CM. Fremanezumab was associated with significant improvements in migraine-specific quality of life outcomes versus placebo in patients with medication overuse at baseline and documented inadequate response to 2-4 classes of migraine preventive medications.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Impact of Fremanezumab on Migraine-associated Symptoms in Patients with Migraine Who Failed 2-4 Classes of Preventive Medications: Results of the Open-label Period of the Phase 3b FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_171;
Fremanezumab was associated with significant improvements in migraine-specific quality of life outcomes versus placebo in patients with medication overuse at baseline and documented inadequate response to 2-4 classes of migraine preventive medications. Reductions in migraine-related symptoms were observed with up to 6 months of fremanezumab treatment in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Impact of Fremanezumab on Headache-related Disability in Patients with Migraine and Inadequate Response to 2-4 Classes of Preventive Medication: Results of the Open–label Extension of the Phase 3b FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_170;
Reductions in migraine-related symptoms were observed with up to 6 months of fremanezumab treatment in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications. Sustained improvements were observed in headache-related disability, based on HIT–6 and MIDAS scores, with fremanezumab treatment over up to 6 months in patients with inadequate response to multiple classes of prior migraine preventive medication.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Impact of Fremanezumab on Disability Severity According to the AHS Consensus: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies () - Jul 15, 2020 - Abstract #AHS2020AHS_169;
Most patients were experiencing severe disability due to migraine at BL. Based upon the recent AHS consensus statement, these results demonstrate the efficacy of quarterly and monthly fremanezumab in patients with migraine, including patients with difficult-to-treat migraine.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Impact of Fremanezumab on Disability in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Classes of Preventive Treatments: Subgroup Analysis of the FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_168;
Based upon the recent AHS consensus statement, these results demonstrate the efficacy of quarterly and monthly fremanezumab in patients with migraine, including patients with difficult-to-treat migraine. Fremanezumab significantly reduced headache-related disability vs placebo in migraine patients with medication overuse and documented inadequate response to 2-4 classes of migraine preventive medications.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Health-related Quality of Life Outcomes with Fremanezumab in Patients with Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Open-label Extension of the FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_164;
Fremanezumab significantly reduced headache-related disability vs placebo in migraine patients with medication overuse and documented inadequate response to 2-4 classes of migraine preventive medications. In patients with EM and CM and inadequate response to 2-4 prior classes of migraine preventive medications, open-label administration of fremanezumab maintained improvements in HRQoL, as measured by both disease-specific and general quality of life questionnaires.
- [VIRTUAL] Establishing a National Real-world Data Pediatric Migraine Registry: Proof of Principle () - Jul 15, 2020 - Abstract #AHS2020AHS_149;
A pediatric migraine registry that collects real-world data is feasible to create and maintain. In addition to collecting data in a regulatory compliant manner, the registry creates a ready for use infrastructure for the conduct of future clinical trials in children and adolescents with migraine.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Efficacy of Fremanezumab Treatment in Patients ≥60 Years of Age with Episodic or Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies () - Jul 15, 2020 - Abstract #AHS2020AHS_135;
In addition to collecting data in a regulatory compliant manner, the registry creates a ready for use infrastructure for the conduct of future clinical trials in children and adolescents with migraine. This pooled analysis demonstrates that fremanezumab treatment was efficacious over 12 weeks in patients ≥60 years of age with EM or CM.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Efficacy of Fremanezumab in Male Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Results of the Randomized, Placebo-controlled FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_134;
This pooled analysis demonstrates that fremanezumab treatment was efficacious over 12 weeks in patients ≥60 years of age with EM or CM. This subgroup analysis demonstrated statistically significant improvements in efficacy outcomes due to the strong effect size versus placebo in male patients, a group for whom the impact of migraine is often underestimated and undertreated.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Efficacy of Fremanezumab by Prior Number of Preventive Treatments with Inadequate Response in Patients with Episodic Migraine and Chronic Migraine: Results of the International, Multicenter Phase 3b FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_133;
For chronic migraine patients with documented inadequate response to 2, 3, or 4 classes of migraine preventive medications, clinically meaningful response rates were significantly greater with fremanezumab compared with placebo. Similar results were observed in EM patients, although some groups were too small to determine statistical significance.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Efficacy and Safety of Fremanezumab in Patients with Episodic and Chronic Migraine and Inadequate Response to 2-4 Classes of Preventive Medications: Results of the Open-label Period of the Phase 3b FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_130;
Similar results were observed in EM patients, although some groups were too small to determine statistical significance. Fremanezumab demonstrated sustained efficacy up to 6 months and was well-tolerated long-term in patients with EM or CM and inadequate response to multiple migraine preventive medication classes.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Effect of Fremanezumab on Depression Status in Patients with Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications During the Open-label Period of the Phase 3b FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_128;
Fremanezumab demonstrated sustained efficacy up to 6 months and was well-tolerated long-term in patients with EM or CM and inadequate response to multiple migraine preventive medication classes. Improvement in depression symptomology (PHQ-9) was maintained during the OLE of the FOCUS study with fremanezumab treatment in patients with CM or EM and documented inadequate response to 2-4 classes of migraine preventive medications.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Disability Severity Category Shift with Fremanezumab Treatment: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies () - Jul 15, 2020 - Abstract #AHS2020AHS_121;
This pooled analysis demonstrated that significantly higher proportions of patients receiving fremanezumab experienced a shift in disability severity of 1, 2, or 3 categories than with placebo. These results indicate that fremanezumab treatment may result in clinically meaningful improvements in headache- or migraine-related disability severity and may be relevant for patients with difficult-to-treat migraine.
- Ajovy (fremanezumab) / Otsuka, Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Cost-effectiveness Sequential Simulation Modeling of Fremanezumab versus Other Therapies for Migraine Prevention from Private and Public Payer Perspectives in Canada () - Jul 15, 2020 - Abstract #AHS2020AHS_117;
Private payer perspective In treatment-naive EM patients, cost-effectiveness of fremanezumab was $14637 (CDN dollars)/success versus $14787 and $16018 for erenumab and galcanezumab, respectively. Fremanezumab is a cost-effective preventive treatment strategy for EM and CM in both treatment-naive patients, and after failure to oral therapies.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Inadequate Response to 2–4 Classes of Migraine Preventive Medication: Results of the Open–label Period of the Phase 3b FOCUS Study () - Jul 15, 2020 - Abstract #AHS2020AHS_107;
Clinically meaningful responses were demonstrated at 6 months in the OLE of the FOCUS study, regardless of whether patients had received fremanezumab or placebo in the double-blind period of the FOCUS study. At the end of OLE, on average, 43% of patients had achieved a ≥50% reduction in monthly average migraine days and 17% a ≥75% reduction.
- Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] CGRP Monoclonals: Efficacy, Side Effects, and Switching () - Jul 15, 2020 - Abstract #AHS2020AHS_102;
In this study of all 3 mAbs, efficacy was reasonable. In our limited number of patients, efficacy after 2 months somewhat predicted how patients would do after 6 months.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] CGRP Monoclonal Antibodies in the Treatment of Migraine in Elderly Patients: A Single Center Experience () - Jul 15, 2020 - Abstract #AHS2020AHS_101;
Our study only included 32 patients who were predominantly female and largely refractory, with multiple prior failed preventives. Additional studies with larger sample sizes are needed to further verify these results.
- Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Calcitonin Gene-related Peptide Inhibitors in the Treatment of Trigeminal Nerve Pain () - Jul 15, 2020 - Abstract #AHS2020AHS_97;
The majority of patients who saw benefit in our sample also suffered from comorbid migraine headaches. Further investigation should be conducted to determine if this benefit is also seen in patients without comorbid migraine headaches, and if this benefit is sustained.
- Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Calcitonin Gene Related Peptide Monoclonal Antibodies in the Treatment of Migraine: Is There a Difference in Efficacy Between Inhibitors of the Ligand Compared to Inhibitors of the Receptor? () - Jul 15, 2020 - Abstract #AHS2020AHS_95;
Overall, our data found no significant differences in treatment response between patients treated with a CGRP mAb to the receptor compared to patients treated with a mAb to the CGRP ligand. Based on this this data, it appears that both mechanisms, inhibiting the ligand or inhibiting the canonical receptor are equally effective in reducing headache frequency and improving quality of life as measured by the HIT-6.
- Ajovy (fremanezumab) / Otsuka, Teva
[VIRTUAL] A Real-world Perspective of Patients with Episodic Migraine or Chronic Migraine Prescribed AJOVY in the United States () - Jul 15, 2020 - Abstract #AHS2020AHS_73;
Based on this this data, it appears that both mechanisms, inhibiting the ligand or inhibiting the canonical receptor are equally effective in reducing headache frequency and improving quality of life as measured by the HIT-6. Patients who were prescribed AJOVY were largely women and approximately 47 years of age, regardless of whether they had EM or CM; however, CM patients had significantly greater numbers of migraine preventive medication prescriptions than EM patients, while EM patients more commonly had comorbid anxiety than CM patients.
- | TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva
Retrospective data, Journal: Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. (Pubmed Central) - Jul 11, 2020
Patients who were prescribed AJOVY were largely women and approximately 47 years of age, regardless of whether they had EM or CM; however, CM patients had significantly greater numbers of migraine preventive medication prescriptions than EM patients, while EM patients more commonly had comorbid anxiety than CM patients. Fremanezumab is a generally safe and well-tolerated preventive therapy for migraine in adults.
- | Journal: Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class. (Pubmed Central) - Jul 11, 2020
Eptinezumab, a CGRP neutralizing antibody given IV, shows promise in late stage clinical development. Recently, orally administered next-generation small molecule CGRP-RAs have been shown to have safety and efficacy in acute treatment (ubrogepant and rimegepant) and prevention (atogepant) of migraine, giving additional CGRP-based therapeutic options for migraine patients.
- || Clinical data, Review, Journal: CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. (Pubmed Central) - Jul 10, 2020
Phase III trials are also currently in progress for the preventive treatment of cluster headache. Conclusion Efficacy of anti-CGRP monoclonal antibodies spells a promising future for the many patients suffering from migraine, and possibly also for the smaller but severely-affected population with cluster headache.
- | Ajovy (fremanezumab) / Otsuka, Teva
New P3 trial: A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age (clinicaltrials.gov) - Jul 8, 2020
P3, N=418, Not yet recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.